Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624067 | 1.00 | TSHR (0.47) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| SCHEMBL29361583 | 1.00 | TSHR (0.47) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| SCHEMBL14038079 | 1.00 | TSHR (0.47) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| SCHEMBL29424095 | 1.00 | TSHR (0.47) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| SCHEMBL11037568 | 1.00 | TSHR (0.47) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL23929292 | 0.92 | PDE4A (0.46) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL23929291 | 0.92 | PDE4A (0.46) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Mucic Acid SCHEMBL23388836 | 0.92 | PDE4A (0.46) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL5974 | 0.92 | PDE4A (0.46) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL2559030 | 0.92 | PDE4A (0.46) | TSHRCYP2C9PDE4AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025263641-A1 | COMPOSITION COMPRISING GLYCOLIPID, CATIONIC POLYMER AND (POLY)HYDROXY ACID | L'OREAL (FR) | 2025-12-26 | — | — | WO | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20250228878-A1 | METHOD FOR THE SYNTHESIS OF EVOC PROBES | OWLSTONE MEDICAL LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4430203-A1 | ASSAY | Owlstone Medical Limited (GB) | 2024-09-18 | — | — | EP | disclosed |
| CN-118574939-A | Measurement | 奥斯通医疗有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4416163-A1 | METHOD FOR THE SYNTHESIS OF EVOC PROBES | Owlstone Medical Limited (GB) | 2024-08-21 | — | — | EP | disclosed |
| CN-118103383-A | Synthesis method of EVOC probe | 奥斯通医疗有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240115469-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2024-04-11 | — | — | US | disclosed |
| EP-4271356-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-116600780-A | Composition for keratin fibres | 莱雅公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023084219-A1 | ASSAY | OWLSTONE MEDICAL LIMITED (GB) | 2023-05-19 | — | — | WO | disclosed |
| CN-115003651-B | Process for preparing aldaric, aldonic and uronic acids | 阿彻丹尼尔斯米德兰公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023062386-A1 | METHOD FOR THE SYNTHESIS OF EVOC PROBES | OWLSTONE MEDICAL LIMITED (GB) | 2023-04-20 | — | — | WO | disclosed |
| CN-115003651-A | Process for the preparation of saccharic, aldonic and uronic acids | 阿彻丹尼尔斯米德兰公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022131141-A1 | MULTI-PHASE COMPOSITION COMPRISING ALPHA HYDROXY ACID | L'OREAL (FR) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022118980-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118982-A1 | PROCESS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118978-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TSHR 3394/4885CYP2C9 4408/4885PDE4A 983/4885 |
| US-20250228878-A1 | METHOD FOR THE SYNTHESIS OF EVOC PROBES | ELOC, ENTPD3, EPCAM | TSHR 4600/4885CYP2C9 4047/4885PDE4A 4364/4885 |
| US-20240115469-A1 | COMPOSITION FOR KERATIN FIBERS | KRT18, COL14A1, KIF5C | TSHR 4801/4885CYP2C9 4102/4885PDE4A 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.